Internship Report
On
GlaxoSmithKline Pakistan
Submitted by:
Ali murad MBA (Marketing)
Batch 09B
Sukkur Institute of Science & Technology
Our values
And
behavior
2
Table of Contents
Acknowledgement 4
Dedication 5
Certificate 6
CHAPTER:1 INTRODUCTION 7
Overview 7
History 8
Mission Statement & Core Values 18
Functions 19
Objectives 20
Purpose of internship 20
Research methodology 20
Limitations 21
CHAPTER:2 ORGANIZED STRUCTURE & SETUP 22
Functions of management 22
Chart of management 24
CHAPTER:3 FUNCTIONS OF VARIOUS DEPARTMENTS 25
HR Department 25
Marketing & Sales Department 30
CHAPTER: 4 PRODUCTS AND SERVICES 33
Manufacturing Sites of GSK Pakistan 35
CHAPTER: 5 SWOT 36
CHAPTER: 6 CONCLUSION/SUGGESTION/PROCEDURE 37
Conclusion 37
Suggestion 37
3
Reference/ bibliography 38
Acknowledgement
Before writing this Acknowledgement I am very thankful to Almighty ALLAH who
gives me ability and courage to complete this Internship Report successfully in a
sophisticated manner. I would like to acknowledge the dynamic guidance and support of
our respectable teachers, who support me from 1st Semester to Last Semester. Without
their guidance, support and guidance this task of completing this Internship Report would
be very difficult. I am very thankful to GlaxoSmithKline Pakistan members who guided
me during entire course of my Internship and gave me their precious time and
information to make the report in proper manner.
I am also thankful to our respectable Director Sir Hassan Bhayo, for his personal efforts
and interest in making the career of the Students bright and beautiful and last but not the
least I feel very great depth of obligation to my parents and other teachers of SISTECH
whose bold commitments, confidence on me and appreciation helped me a lot to prove
myself.
I am in short of word to express my modest gratefulness and recognition to cuddly and
loveable “Parents and Members of Family” who each and every moment pray for my
Success.
I also pay appreciation to my Friends. I am also thankful to all my Teachers who taught
me from Childhood to still.
My special thanks to my Regional Sales Manager Mr. Syed Irfan Ali and Mr. Jawed
Iqbal Kaim Khani who help me extra ordinary and guide me each and every Step and
give me useful information for to learn more and more.
I feel great pride and pleasure on accomplishment of this Report
4
Dedication
“Confidence comes from Hours and Days
And Weeks and Years of Constant Work and Dedication”
At first dedicating this Work to Almighty ALLAH without his mercy and Sympathy I
was not able to accomplish this work.
This humble effort is dedicated to my honorable
PARENTS
Who did their best to uplift me to the height of and ideal life and whose affections
inspired me to love Mankind and respect others
TEACHERS
Who built my moral and made possible me to achieve the height of ideal life.
FRIENDS
Who always helped me in preparing this Internship report and all types of matter.
5
CHAPTER: 1 INTRODUCTION
Overview
GlaxoSmithKline Pakistan Limited was created January 1st, 2001 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan (Private) Limited and Glaxo Wellcome (Pakistan) Limited- standing today as the largest pharmaceutical company in Pakistan. As an industry leader we are committed to our mission of providing patients quality products to help improve their lives. GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.
Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
But being a leader brings responsibility. This means that we care about the impact that we have on the people and places touched by our mission to improve health around the world.
It also means that we must help developing countries where debilitating disease affects millions of people and access to life-changing medicines and vaccines is a problem. To meet this challenge, we are committed to providing discounted medicines where they are needed the most.
As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs. Every hour
We spend more than £300,000 (US$562,000) to find new medicines.
We produce medicines that treat major disease areas such as asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.
We also market other products, many of which are among the market leaders:
Over-the-counter (OTC) medicines including Iodex, Eno, Calplol and Panadol
Dental products such as Aquafresh and Sensodyne
Smoking control products Nicorette/Niquitin
Nutritional healthcare drinks such as Lucozade, Ribena and Horlicks
Skincare products marketed by Stiefel Laboratories
7
History of GlaxoSmithKline World wide
1830John K Smith and his brother-in-law, John Gilbert, opened a drugstore in Philadelphia in 1830. When John Gilbert decided to withdraw, Smith was joined by his younger brother George. The company soon became a leader in drug wholesaling.1842 Thomas Beecham launches the Beecham's Pills laxative business in England. The laxative is to become widely successful.
1859
Beecham opens the world's first factory to be built solely for making medicines at St Helens in England.
1865
Mahlon Kline joins Smith and Shoemaker - as John K Smith and Co had become - as a bookkeeper
1873
Joseph Nathan, who left the UK to seek new business opportunities 20 years before, establishes a general trading company at Wellington in New Zealand - Joseph Nathan and Co - the foundation for the Glaxo company to be formed later.
1875
Mahlon Kline took on additional responsibilities as a salesman and added many new and large accounts. He is rewarded when the company, Mahlon K Smith and Company, is renamed Smith, Kline and Company.
8
1880
Burroughs Wellcome & Company is established in London by American pharmacists Henry Wellcome and Silas Burroughs, four years after Joseph Nathan opened a London office.
1884
Tabloid is registered as a Burroughs Wellcome and Company trademark to describe its compressed tablets
1885
Thomas Beecham's company acquires headquarters on the corner of Silver Street and Water Street, St Helens, England. Two years later, the company's new factory in St Helens becomes the first in the area to have electricity
1891
Smith, Kline and Company acquires French, Richards and Company, providing a greater portfolio of consumer brands
1902
The Wellcome Tropical Research Laboratories open
1904
Nathan starts dried milk powder production in New Zealand, exporting to London. Henry Wellcome hires Henry Dale, who is to discover and study, among other things,
1913
Production of Beecham's Pills laxative reaches one million a day.
1919
Alex C Maclean establishes Macleans Ltd, manufacturing own-name products for chemists. Mahlon Kline begins the novel practice of sending pharmaceutical samples through the mail to doctors across the US.
9
1924
The vitamin D preparation Ostelin becomes Glaxo's first pharmaceutical product. The Wellcome Foundation Ltd is formed. The Beecham estate is purchased by Philip Hill, who realised that the Beecham's Pills business could, through diversification, become the basis of a major company.
1926
Beecham's Powders cold remedy is introduced
1929
Smith, Kline and French Company is renamed Smith Kline and French Laboratories and becomes more focused on research.
1930
Sydney Smith of Wellcome isolates the glycosides of Digitalis lanata, a variety of foxglove. Lanoxin (digoxin) is used in the treatment of heart failure.
1935
Glaxo Laboratories is formed and new facilities are created at Greenford, near London.
1936
Sir Henry Wellcome's will leaves sole ownership of The Wellcome Foundation Ltd to a UK medical research charity, today called the Wellcome Trust. Sir Henry Dale of Wellcome is awarded the Nobel Prize for Medicine for his work in the chemical transmission of nerve impulses
1938
Beecham acquires Macleans Ltd and Eno's Proprietaries Ltd. Macleans toothpaste and Lucozade energy-replacement drink are added to Beecham's product line
1943
Beecham Research Laboratories is formed with the mission to focus exclusively on basic pharmaceutical research.
1945
Beecham Group Ltd is established, replacing Beecham Pills Ltd and Beecham Estates Ltd - later known as Beecham Group plc - and incorporates Beecham Research Laboratories.
10
1947
glaxo Laboratories Ltd absorbs the Joseph Nathan company and becomes the parent company. Glaxo is listed on the London Stock Exchange. New Beecham laboratories are established at Brockham Park in Surrey, England.
1948
Vitamin B12 is isolated by Glaxo scientists for the treatment of pernicious anaemia. Streptomycin for TB treatment is produced by Glaxo scientists. Polymixin anti-bacterials are developed by Wellcome. Smith Kline and French Laboratories acquire a new site at 1530 Spring Garden Street, Philadelphia.
1949
Beecham Group Ltd acquires C L Bencard Ltd, a company specialising in allergy vaccines. It is a first step towards ethical products for the Beecham company.
1953
Wellcome launches its antileukaemic drug Purinethol (mercaptopurine).
1958
Glaxo acquires Allen and Hanburys Ltd.
1959
The Wellcome Foundation acquires Cooper, McDougall and Robertson Ltd, an animal health company founded in 1843.
1958-1959
Wellcome launches range of Actifed antihistamine products for head colds and allergies.
1960
Smith Kline and French launches Contac, the cold remedy, using the Spansule to release an initial major therapeutic dose, followed by numerous smaller doses, over 10-12 hours.
11
The company moves into the animal health business with the acquisition of Norden Laboratories.
1963
Betnovate (betamethasone) becomes the first of Glaxo's range of steroid skin disease treatments. In the mid-1960s, Smith Kline and French acquires RIT (Recherche et Industrie Therapeutiques), a vaccines business.
1968
Septrin (co-trimoxazole) anti-bacterial from Wellcome is introduced.
1969
Glaxo launches Ventolin (salbutamol) for asthma, developed at Ware and marketed under the Allen and Hanburys name. Ceporex, Glaxo's first oral cephalosporin antibiotic, is introduced. Smith Kline and French enters the clinical laboratories business through the purchase of seven laboratories in the US and one in Canada.
1970
Burroughs Wellcome Inc moves its production facility from New York to Greenville, North Carolina.
1971
Wellcome launches its rubella vaccine. Burroughs Wellcome Inc opens its research site at Research Triangle Park, North Carolina.
1972
Scientists at Beecham Research Laboratories discover amoxicillin and launch Amoxil, to become a widely-used antibiotic. Beecham Group plc is unsuccessful in its bid for Glaxo Group Ltd - and Glaxo is unsuccessful in its attempt to merge with UK chemists Boots. Inhaled steroid beclomethasone dipropionate is launched by Glaxo as Becotide (beclomethasone dipropionate) for asthma, followed in 1975 by Beconase for rhinitis conditions.
1976
The H2 blocker Tagamet (cimetidine) is introduced in the UK by the SmithKline Corporation, and in the US in the following year. The treatment will revolutionise peptic ulcer therapy.
1978
12
Through the acquisition of Meyer Laboratories Inc, Glaxo's business in the US is started, to become Glaxo Inc from 1980. The broad-spectrum injectable antibiotic Zinacef (cefuroxime) is introduced by Glaxo.
1981
The anti-ulcer treatment Zantac (ranitidine) is launched by Glaxo and is to become the world's top-selling medicine by 1986. Augmentin (amoxicillin / clavulanate potassium), to combat a wide range of bacterial infections in children and adults, is launched by Beecham. The antiviral Zovirax (aciclovir) is launched by Wellcome for herpes infections
1982
SmithKline acquires Allergan, an eye and skincare business, and merges with Beckman Instruments Inc, a company specialising in diagnostics and measurement instruments and supplies. The company is renamed SmithKline Beckman. John Vane of the Wellcome Research Laboratories is awarded the Nobel Prize, with two other scientists.
1983
Glaxo Inc moves to new facilities in Research Triangle Park and Zebulon, North Carolina. The broad-spectrum injectable antibiotic Fortum (ceftazidime) is launched. Wellcome launches Flolan (epoprostenol) for use in renal dialysis.
1986
Beecham acquires the US firm Norcliff Thayer, adding Tums antacid tablets and Oxy skin care to its portfolio.
1987
The AIDS treatment Retrovir (zidovudine) is launched by Wellcome. Glaxo introduces the oral antibiotic Zinnat (cefuroxime axetil).
1988
SmithKline BioScience Laboratories acquires one of its largest competitors, International Clinical Laboratories, Inc, increasing the company's size by half and establishing SmithKline BioScience Laboratories as the industry leader. The Nobel Prize for medicine is awarded to George Hitchings and Gertrude Elion, of Burroughs Wellcome Inc, and to Sir James Black, who had worked at the Wellcome Foundation and Smith Kline and French Laboratories.
1991
13
Glaxo launches its novel treatment for migraine, Imigran (sumatriptan), Lacipil (lacidipine) for high blood pressure, and Cutivate (fluticasone propionate) in the US for skin diseases. SmithKline Beecham moves its global headquarters to New Horizons Court at Brentford, England. SmithKline Beecham's Seroxat/Paxil (paroxetine hydrochloride) is launched in the UK, its first market.
1992
Mepron (atovaquone) for AIDS-related pneumonia is introduced by Burroughs Wellcome in the US. SmithKline Beecham's Havrix hepatitis A vaccine, inactivated, the world's first hepatitis A vaccine, is launched in six European markets.
1993
SmithKline Beecham and Human Genome Science negotiate a multi-million-dollar research collaboration agreement for identifying and describing the functions of the genes in the human body. Glaxo introduces Flixotide (fluticasone propionate) for bronchial conditions.
1994
SmithKline Beecham purchases Diversified Pharmaceutical Services, Inc, a pharmaceutical benefits manager. Sterling Health also is acquired, making SmithKline Beecham the third-largest over-the-counter medicines company in the world and number one in Europe and the international markets. With the intention of focusing on human healthcare, SmithKline Beecham sells its animal health business.
1995
Glaxo and Wellcome merge to form Glaxo Wellcome. Glaxo Wellcome acquires California-based Affymax, a leader in the field of combinatorial chemistry. The Queen opens Glaxo Wellcome's Medicines Research Centre at Stevenage in England. Valtrex (valaciclovir) is launched by Glaxo Wellcome as an anti-herpes successor to Zovirax (acyclovir). SmithKline Beecham acquires Sterling Winthrop's site in Upper Providence, Pennsylvania, to fulfil US R&D expansion needs.
1997
SmithKline Beecham's research centre, New Frontiers Science Park, opens at Harlow in England. SmithKline Beecham and Incyte Pharmaceuticals create a joint venture - diaDexus - to discover and market novel molecular diagnostics based on the use of genomics.
1998
14
SmithKline Beecham and the World Health Organization announce a collaboration to eliminate lymphatic filariasis (elephantiasis) by the year 2020. The largest pharmaceutical company in Poland is created with the acquisition of Polfa Poznan by Glaxo Wellcome.
1999
The 30th anniversary of the launch of Ventolin (albuterol) is marked as respiratory becomes Glaxo Wellcome's largest therapeutic area. Sharpening its focus on pharmaceuticals and consumer healthcare, SmithKline Beecham divests SmithKline Beecham Clinical Laboratories and Diversified Pharmaceutical Services. SmithKline Beecham's Avandia (rosiglitazone maleate), for the treatment of type 2 diabetes, is launched in the US.
2000
GlaxoSmithKline is formed through the merger of Glaxo Wellcome and SmithKline Beecham.
2001
GSK moves to its new UK headquarters in Brentford, West London. GSK House consists of four, five-storey buildings and a 16-storey tower block linked by an internal fully-glazed 'street'. The building was designed with input from employees. Twinrix, the first combination vaccine to prevent hepatitis A and B is approved by the FDA. GSK reorganises its research and development efforts into Centres of Excellence for Drug Development (CEDDs), small business units that emphasise flexibility, innovation and therapeutic focus. GSK launches Advair, an anti-asthma medicine, in the US and acquires the Sensodyne range of oral care products. GSK launches the African Malaria Partnership to help combat a disease that kills more than one million people every year.
2003
On 27 July 2003, ten million people in Sri Lanka received free doses of GSK-donated albendazole to help prevent the transmission of lymphatic filariasis. GSK launches Wellbutrin XL, an anti-depressant medicine, in the US.
2004
15
GSK ships 33 million tablets of preferentially-priced Combivir (HIV treatment) to Africa.
GSK launches its Clinical Trial Register, an Internet site containing clinical trial data that anyone can access. GSK is the first pharmaceutical company to offer this level of transparency for its clinical trial data.
2005
GSK launches Rotarix, a vaccine against rotavirus, a major cause of vomiting and diarrhoea in infants. The launch programme of the product focuses on markets where the need is highest. GSK donates medicines and vaccines in response to the Asian Tsunami disaster of December 2004 and devastation caused by Hurricane Katrina in the USA in August 2005. GSK announces the FDA approval of Fluarix GSK take steps to bolster it leadership position in pandemic flu preparedness by investing in flu vaccine production facilities, the acquisition of vaccines production facilities and the development of candidate pandemic flu vaccines.
2006
GSK produces over 10 million packs of its anti-flu treatment Relenza in one year. To boost its consumer healthcare portfolio, GSK acquires CNS Inc
2007
In a busy year for acquisitions, GSK acquires Domantis, a leader in developing antibody therapies, Praesis Pharmaceuticals, a biopharmaceuticals company and Reliant Pharmaceuticals, a producer of cardiovascular medicines.GSK launches alli, over-the-counter orlistat, for first FDA-approved treatment for obesity in the US. New R&D centre opened in China.
2008
GSK marks the ten year anniversary of its commitment to eliminate lymphatic filariasis.
New allergic rhinitis treatment Avamys approved in Europe. GSK reduces prices for anti-retrovirals in the world's poorest countries. GSK ceases providing corporate political contributions.
2009
16
Weight loss medicine alli launches in Europe. Synflorix, GlaxoSmithKline‘s pneumococcal vaccine, receives European authorisation.GSK‘s commitment to emerging markets is strengthened through agreements with Aspen, Dr. Reddy‘s and UCB. GSK becomes a leader in skincare with the acquisition of Stiefel. advances in treatment and care for HIV communities. Agreement reached to launch Lucozade in China. GSK‘s H1N1 Pandemrix vaccine receives European Commission Approval. Cervarix approved in USA and Japan. World‘s largest malaria vaccine trial gets underway in seven African countries. GSK signs agreement with the World Health Organization to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries. GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed. As part of its commitment to greater transparency, GSK publishes speaking and consulting fees paid to US physicians.
2010
GSK becomes acquired Bristol-Myers Squibb Products in Pakistan and Egypt.
History of GlaxoSmithKline Pakistan Limited
GlaxoSmithKline, Pakistan (GSKP) Limited is the largest research-based pharmaceutical company in the country and the second largest in the world. GSK have been represented in Pakistan since 1955, which puts in a great position to make a difference to our community and promote good corporate citizenship.
We strive to be valued corporate citizens no matter where we do business. We have always shown strong commitment and support for public health and awareness initiatives and have championed many social causes. In the face of growing adversity, especially in the developing world, GSK have responded through three main channels: preferential pricing (vaccines and anti-virals being offered on non profit basis/discounts), research and development and community investment. The Group's strong commitment to the community is reflected in various charitable projects in Pakistan, and around the world. GSK relationship with our various communities is something we are very proud of as individuals and as an organization.
According to the Guardians Giving List: GSK was at 6th place before any other pharmaceutical company, with the highest overall gift in kind quantity and the third highest overall cash donation of £61 million in 2006.
GSK Pakistan was also awarded the prestigious Management Association of Pakistan (MAP) award for which nominations are based on independent evaluation of quality of management practices including corporate governance, marketing planning, production, R&D and corporate social responsibility and also financial performance. Awards are
17
given in two categories - Business & Industrial and Financial and GSKP won the overall Corporate Excellence Award in the Business & Industrial category by obtaining the score across all sectors in 2007.
18
Mission Statement
Excited by the constant search for innovation, we at GSK undertake our quest with the enthusiasm of entrepreneurs. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Quality is at the heart of everything we do- from the discovery of a molecule to the development of a medicine.
GSK Values
GSK values are deeply embedded in every function, across the globe. Strategic development, operations, and customer engagement are based on our values of
Vision Statement
To create and sustain value by recognized as a pharmaceutical industry leader valued by patients and the health care providers, sought after as an employer, and respected by the scientific community and by our competitors.
Functions
Our corporate functions are based at GSK House in West London, and work with various different business areas to deliver against overall organizational goals.
As well as benefits, compensation, recruitment, organization and leadership development, and employee health management, the HR team is also responsible for operations, strategy, communications and systems.
Our 2011 Industrial Placement Opportunities exist for students who are currently undertaking a business related degree and can demonstrate a genuine interest in Human Resource Management.
19
Objectives
As a leading international pharmaceutical company we make a real difference to global healthcare and specifically to the developing world. We believe this is both an ethical imperative and key to business success. Companies that respond sensitively and with commitment by changing their business practices to address such challenges will be the leaders of the future. GSK Pakistan operates mainly in two industry segments: Pharmaceuticals (prescription drugs and vaccines) and consumer healthcare (over-the-counter- medicines, oral care and nutritional care).
GSK Pakistan leads the industry in value, volume and prescription market shares, and we are committed to our mission of providing patients quality products to help improve the quality of their lives. Some of our leading pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and renowned consumer healthcare brands, which include Panadol, Horlicks, Aquafresh, Macleans and ENO
At GSK, we firmly believe that operating in a responsible and ethical way
is essential for the success of our business. We have come a long way but
recognise that there is much more we can do and we will continue to
challenge ourselves.
CEO Sir Andrew Witty
Purpose of Internship
The main purpose of this internship report is to fulfill the partial requirement of the degree of MBA and to become familiar with the practical working conditions of business organization. To measure the gap between theory and practice.
Research Methodology
The research will be composed of l iterature review for theories and qualitative research mainly. An extensive study of the research methodology literature will be the base. Then the practical experiences and observations from the project worked for during internship will be compared with the li terature. Finally qualitative in-depth interviews and key informant interviews will lead us to our answers. Mostly Primary data are used in Internship, but Secondary data also used due to unavailability of Primary Data.
20
Limitations
It is very obvious that there should be some limitations in organization while working, because with lots of co-operative and polite attitude they kept many things some matters away from me, just like they didn't allow me for working in field and working with distribution sales officer as well.
21
CHAPTER: 2 ORGANIZED STRUCTURE & SETUP
Definition of Organization
An organization is a group of people associated for business, political, professional, religious social or other purpose. In other words we can say that any group of people who have some goal with formal agreement may be an organization.
Organizational Chart
An organization chart is defined as a clear set of relationship among the member of an organization. Management organizational structure shows who is responsible for what & who is to report to whom. It's also sets the routs along which information flows both up & down the chain of command.
Functions of management
Board of Directors
Salman Burney
Rafique Dawood
Husain Lawai
Maqbool-ur-Rehman
Erum Shakir Rahim
Fariha Salahuddin
Dr. Muzaffar Iqbal
Shahid Mustafa Qureshi
Yahya Zakaria
Mehmood Mandviwalla
22
Management Committee
Salman Burney
Dr. Muzaffar Iqbal
Erum Shakir Rahim
Fariha Salahuddin
Shahid Qureshi
Yahya Zakaria
Maqbool ur Rehman
Sohail Mateen
Dr Atif Mirza
M. Salman Burney - Managing Director
Dr. Muzaffar Iqbal - Technical Director, Global Manufacturing and Supply
Pervaiz Iqbal Awan - Director Sales BU-I
Maqbool Ur Rahman - Director Sales BU-II
Erum Shakir Rahim - Director Marketing & Business Development
Javed Ahmedjee - Director Finance, IT & Logistics
Shahid M. Qureshi - Director Legal, Corporate Affairs, IR, Admin and Regulatory
Fariha K. Salahuddin - Head of Human Resource and Organisational Development
Dr. Yousuf Khan - Director Medical Affairs and R&D
Sohail Matin - Country Manager, Consumer Healthcare
23
Managing Director
Director HR
Director BU I
Director BU II
Director Marketing
& BDDirector Finance
Director Legal
Technical Director
Director Medical
National Sales
Manager
Sales Manager
Regional Sales
Manager
Medical Services
Executive
Group Product Manager
Product Manager
Brand Manager
Assistant HR
Manager
HR Manager
Chart of Management
24
CHAPTER: 3 FUNCTIONS OF VARIOUS DEPARTEMENTS
Human Resources Department
25
GlaxoSmithKline has a very extensive HR department, which always busy to develop the company's capability & seeks to facilities the contribution among the employees to achieving the company's goals. The HR department creates the strategies & innovation for which companies noted. As slogans of GSK our challenges is life. The HR department activities contributed to company's success in a variety of ways, like HR department responsible to hire the people according to the job description. In recruitment process GlaxoSmithKline invest the money for hiring the right candidate. GlaxoSmithKline department of the products, every year HR department spend the certain amount on the R&D department.
Recruitment & Selection Process
GlaxoSmithKline has very qualitative recruitment & selection process. In which HRD plays very important role to hire the employee. When the company conducts the interviews in which HR members & departments' members select the candidate. In GlaxoSmithKline recruitment & selection process has some steps which are followed in recruitment process.
Selection Process
26
Failed to meet minimum qualification
Failed to complete application or job specification
Failed Test
Failed to impress interviewer & or meet job
Specification
Problem encountered
Unfit to do essential elements of Job
Able to perform essential elements of Job
Creating a High- Performances Culture
Med / Phy Examination
Reject Application
Employment Test
Comprehensive Interview
Background Checks If required
Final Job Offer
27
GlaxoSmithKline wants to align employee with the key success factors of our business and to give them incentive to concentrate their efforts in areas where the biggest difference can be made and the greatest benefits achieved. Performance and talent 'management area the two pillars of clear for goal settings, performance review and training.
Training and Skills Development
GlaxoSmithKline is an innovation driven company, it is essential to promote the renewal and development of individual skills of our employee. Therefore, they are fostering and making environment that establishes an expectation of continual learning, innovation and creativity to achieve outstanding performers.
GlaxoSmithKline intends to support our employee, personal development efforts and provide them the necessary training programs to perform their function and to develop their capabilities. Individual development planning begins our performance process.
The purpose of the annual performance review is not only to assess annual achievements and to agree on individual objectives, but also to discuss career aspirations; and possible personal development. During this discussion, the employee and the manager on what is needed to further develop the employee in the current job and lot prepare the employee for other positions. Based on this exchange between employee and manager, training program and the other activities are identified that update and enlarge the knowledge of our employees and also improve their employability.
What information designed is to attract, retain and motivate the best people.
Talent Management
Through the talent management process, we address organizational issues that are important to our business success. The aims are to identify talent recruitment based on business need, assess individual and organizational potential, review talent and address gaps in our talent pipeline. By identifying successors for key positions, we can define coaching and development plans and future moves. And where gaps exist, we will fill them by recruiting suitable candidates. Differentiation increases motivation and retention of our best performers; it also clarifies the need for establishing development plans for our talent.
Participate, purchased 2.3 million new shares under the plan, even though the stock market environment was very volatile at the time of the offering. A similar plan was offered in 2000.
Using the Leadership Profile a tool for Managers & PA’s
The leadership profiles one of sanofi aventis mangers most important tools. It is linked to major people-related process that managers use to identify and develop the people who make certain that sanofi aventis is a leader in global pharmaceuticals markets.
Hiring and Staffing
Besides the functional / technical aspects, the leadership profile sets the criteria for selecting the individuals who have the best qualifications and skills to be successful in leadership positions to be filled.
28
Training
GlaxoSmithKline use the leadership profile to focus individual training on the success factors which has been identified as critical for GSK success.
GlaxoSmithKline principle of Total Reward
GSK offers a reward program designed to attract, retain and motivate the people who are critical for reaching the goal of our performance driven company.GSK reward program reinforces the partnership between the company and its associates by providing a clear line of sight between individual's performances and rewards linked to business results.GSK taken together, their plans that comprise total reward are competitive with comparable pharmaceuticals and related companies in the location where we operate.GSK provides a competitive benefits package designed to support the current and future needs of a diverse population.
Compensation Plan
The successful transformation of GlaxoSmithKline into a pure pharmaceutical company is due first and foremost to our employees. Their commitment to business goals and dedication to customer needs are the foundation of our progress.
GSK has established policies and practices designed to make us an employee of choice in our industry. We have a worldwide employment approach based on two principles: respect for legal requirements in each country where we operated and respect for people and organization representing our employees.
o Competitive compensation and reward system.o Increasing focus on talent management.o Training and skills development.o Workplace diversity.o Global employee opinion survey.o Europeans work council.o Employee share ownership.
GSK Components of Total Compensation Plan:-
Our Total Compensation Components
Employee benefits and perquisites
Long term incentives
Short term incentives
Base salary
o Base salary is fixed o Long term and short term incentives are variable.
29
Base Salary
Their basic salary ranges are locally developed to be competitive in each country. The application of these ranges to what individuals are actually paid reflects performances, skills, competency level and experience.
Short-Term Incentives
This compensation component, their annual incentives plan, provides cash awards to eligible associates around the world. The target awards levels are developed to be competitive and to meet local market requirements. Their annual incentive is to use the annual incentive plan to drive and reward better-then industry performances.
Marketing System
GSK has very huge and effective marketing system, which is always busy to provide support to the sales, management teams when planning, analyzing and evaluating alternative strategies. GSK believe on an effective marketing system which can help to capture the market and enhance the profitability of the company by using the effective marketing plans.
Daily Sales Report
The account officers compile this report after gathering the product wise primary sales figures of all the areas from depot and email it to the head office and daily basis. This report depot target this month, sales this month/last month/on had.
Graphical Analysis of Sales
Mostly this activity applies at head office, through graphical analysis they analyze the current sales position national and area wise.
1. Daily sales analysis (using Bar Charts) (Distributor Sale, Salesman wise sale, Route wise sale, Brand wise sale, Brand shop sale)
2. Daily sales analysis (using line charts) 3. Brands share (using pie charts) 4. M/Sales Analysis (using bar charts) 5. M/Sales Analysis (using line charts)
GSK leadership profile
Business success demands effective leadership. Leader must communicate a clear vision provide a sense of direction and motivate others to follow that direction. At GSK, our goal is to consistently have quality leadership across the entire organization.
Therefore we developed our town leadership profile to help our managers focus on the leadership capabilities we will need to address our business challenges successfully in the competitive pharmaceuticals market.
GSK leadership profile includes five success factors
Deliver strategic business results
30
Demonstrates personal leadership
Build the global organization
Develop human capital
Transforms and reinvent the business
Deliver strategic Business Results
Focus on customers and market value creation.
Establish a compelling vision with clearly focused priorities.
Drive for Speed in decisions and action.
Integrate and balance global and local perspectives.
Marketing & Sales Departments
Sales Promotion
Promotion is adding values and bringing innovative style of promotion to activate & communicate merit of the products and purses the target customers to buy it.
GSK has a great concern for the promotion of its products. The all Pharma Associates are totally equipped with scientific knowledge about the products & they know how-to compete the other competitors.
This makes the difference in the market that's why GlaxoSmithKline is known by the name of "research base organization in allover the world". Special posters are designed stalls are set at different occasions. These stalls run a promotion called "sure win" which offered customers an instant win (with 100% incidence) on prescription of the product.
This kind of stalls ranges the special events like conference etc.
Drug Information Systems
GSK has information system which's always looks to the new information regarding the disease or product. This department provides the latest information to company's employee as well as to customer on request. This department is specially controlled or run by the doctors & scientist too. This department is responsible to search new information for customers (doctors).
Duties and Responsibilities
Medical Service Executive Sukkur Region will report to Regional Sales Managers
Updating of Scientific knowledge
31
Making Business Plan Quarterly
Implementation of Marketing Activities
Managing Accounts by sharing of scientific Knowledge
Identifies the weak & potential areas which can cover to meet the Business goal
Implementation of SOPs
Arrangement of Scientific Product Presentations & Round table discussion With highly sophisticated Physicians or Specialists Collect the Daily Sales from distributors and convey to District Managers
Experience sharing with Pharma Associates on weekly meetings
Abide by all instruction from Information Solution department
Any special task assigned by Sales Manager
Accomplishments
Duties Time Line
o Orientation 01 Day
1. IJSFA Two Weekso Entry of Call Plan manual & computerized 02 Dayso Entry of Travel Plan manual & computerized 01 Dayo Develop Dr List 02 Dayso Red Book 01 Dayo Coverage 02 Dayso SFPI 03 Dayso Addition and Deletion of Drs 01 Days
2. General Administration Two Weekso Log Books 03 Dayso House Keeping 01 Dayso General Work 02 Dayso Arrangement
Promotional Activities Inside & Outside 03 Days HR & other supporting Activities 03 Days
32
3. Sales Three Weekso Daily Sales Performa 01 Dayo Weekly & Monthly Sales Performa 01 Dayo YTD & Growth Sales Chart 01 Dayo Value Wise & Product Wise Sales Chart 01 Dayo Geographical Sales Performa 02 Dayo Business Review Package of Sukkur Region 06 Dayo Expense Performa (DM & P A) 02 Dayo Forecast sales & Target distribution 02 Dayo Sale Force Leadership Plan 02Day
4. System Administration Five Dayso Troubleshooting of Software and Hardware 01 Dayo Network (LAN) 01 Dayo Mail Server 01 Day
CHAPTER: 4 PRODUCTS & SERVICES
33
GSK Pakistan currently working with following Products.
Core Product Portfolio Strategic Product Portfolio
Augmentin Antibiotic Arixtra Anti-Coagulant
Septran Antibiotic Avodart BPH
Calpol Antipyretic Maxipime Antibiotic
Zinacef Antibiotic Zofran Antiemetic
Velosef Antibiotic Capoten Antihypertensive
Ceporex Antibiotic Cutivate Antifungal
Zantac PPI Panadol Antipyretic
Polyfax Antibiotic Engerix Vaccine
Betnovate Antifugal Zefix Vaccine
34
GSK Manufacturing Sites in Pakistan
GMS West Wharf
This manufacturing site is located on the sea shore close to the Karachi Port and city centre. The major manufacturing operations at this site are Dermatological products, Ointments and Creams, including a sterile facility for liquid ampoules. The West Wharf site also has a small unit for aerosols and spansules manufacturing. Over a 100 Stock Keeping Units (SKUs) are manufactured here, with an annual volume of around 120 million packs.Major products manufactured at this site are Betnovate, Dermovate, Polyfax and Fefol Vit.
GMS F 268, SITE Karachi
This site is located in the Sindh Industrial Trading Estate and is the biggest GMS site in Pakistan. It has three manufacturing blocks - Liquid Block, Tablets Block and a dedicated Penicillin Block. The site also has a small dedicated unit for Iodex Cream. Over 120 SKUs are manufactured at this site, with an annual volume of around 185 million packs. Major products manufactured at this site are Augmentin, Amoxil, Calpol, Zantac and Actifed.
GMS Korangi, Karachi
Located in the Korangi Industrial State, this manufacturing site has a dedicated block for Cephalosporin, both orals and injectables, as well as a small unit for tablets. GMS Korangi manufactures around 50 SKUs and produces an annual volume of around 25 million packs. A major product manufactured at this site is Velosef.
GMS Lahore
This site is located on Ferozepur Road in Lahore and has a dedicated manufacturing unit for Cephalosporin’s orals and injectables. The site manufactures around 15 SKUs with an annual production volume of around 8 million packs. Major products manufactured at this site are Fortum, Zinacef and Ceporex.
CHAPTER: 5 SWOT
35
Strength
Interdicting new and research products. Ethical marketing approach. Up grading the products by utilizing the market knowledge as well as
information. Effective human resource department which is always busy to coordinating the
whole organization function Good training and development activates for employees.
Weaknesses
Limited Pharma Associates and District Manager as compared to leading National Companies..
Less number of activities done by product management side s compared to GSK and Novartis (MNCs)
Opportunities
High concentration on new accounts. Government campaign to promote cardiac products and oncology products. Industry growth or market growth. Research molecules in pipe line.
Threats
Large number of competitors. High cost and due to high cost high price. Government policies for high price products. Unethical practices from competitors.
CHAPTER: 6 CONCLUSION/SUGGESTION/PROCEDURE
36
Conclusion
During the internship, I have observed that all the departments of the organization doing their job in a defined format. I have observed that there is room for little improvement in a few department of the company.
1. It is seen that there is no proper communication in the organization upward.
2. The Distribution Channels are covering a huge territory, that's why they are unable to cover the market extensively.
3. They do not have realistic approach in target setting and facing difficulties in achieving target
4. They have been facing problems in the execution of planning.
Suggestion
1. Communication is the life blood for any organization; they should have smooth down ward and up ward communication so that the customer’s complaints or queries can easily resolve.
2. The budgets of the entire field force should be on rationale basis, higher targets may lead to turnover.
3. Organizations make professionals, every organization focuses on process of continuous improvement that will bring drastic improvement in the internal environment of the organization, and GSK as a giant should also adopt these policies for front line team which will increase the status of GSK in the pharmaceuticals industry.
4. Customers are not satisfied with the distributions management in terms booking & supply, they should put into operation some latest technology in it with using electronic devices for just in time delivery.
37
Reference/ bibliography
Philip Kotlar
www.gsk.com.pk
Employee Handbook
IJSFA
Miss Fariha salauddin HR Director
Mr.Maqbool Rehman Head of Core Business
Mr.Zulfiqar Ali National sales Manager
Mr Jawed Iqbal Kaim Khani Regional Sales manager - Sukkur
Mohammad Qasim MSE - Sukkur
38